S100-derived peptide (ELKVLMEKEL) was found to compete for the RAGE site required to bind ligands, such as S100P, S100A4, and HMGB1, and reduced RAGE-mediated NF-κB activation, inflammation, tumor growth, and metastasis in different cancer cells [105]. This evidence concerns the gene S100B and neoplasm.